(Q24201712)

2

0 references

Jian Guo

3

0 references

Muke Zhou

4

0 references

Cairong Zhu

5

0 references

Li He

Cochrane Database of Systematic Reviews

6

0 references

publication date

31 January 2013

0 references

published in

0 references

cites work

Effects of cerebrolysin on moderate cognitive impairments in cerebral vascular insufficiency (a clinical-electrophysiological study).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Vascular dementia: emerging trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Diagnostic criteria of vascular dementia in CADASIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

The prevalence of dementia in the People's Republic of China: a systematic analysis of 1980-2004 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Does blood pressure lowering treatment prevents dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Cerebral blood flow in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Huperzine A for vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Vascular cognitive impairment: current concepts and clinical developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Vascular cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Vascular cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Hachinski's ischemic score and the diagnosis of vascular dementia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Cerebrolysin: a review of its use in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Spotlight on cerebrolysin in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Low Baseline Bispectral Index of the Electroencephalogram in Patients with Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Long-term cognitive transitions, rates of cognitive change, and predictors of incident dementia in a population-based first-ever stroke cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Vascular risk factors and dementia: how to move forward?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Yizhi capsule for vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Prevalence of dementia and major dementia subtypes in the Chinese populations: a meta-analysis of dementia prevalence surveys, 1980-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Cerebrolysin for acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Cerebrolysin in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

Neurotrophic activities and therapeutic experience with a brain derived peptide preparation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

7 January 2021

The dentate gyrus neurogenesis: a therapeutic target for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

7 January 2021

Effects of Cerebrolysin on the outgrowth and protection of processes of cultured brain neurons

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

7 January 2021

A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

7 January 2021

Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

7 January 2021

Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008900.PUB2

7 January 2021